Company / Net Income
Anika Therapeutics, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$10.9M
FY2025
5-year range
-$82.7M / $27.2M
FY2021-FY2025
Trend
+80.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 10 years, ranging from -$83M in FY2023 to $38M in FY2016.
Based on SEC 10-K filings.
-$11M in FY2025.
Improved from -$83M to -$11M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income increased 80.7% year-over-year.
- Peak net income was recorded in FY2016.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$10.9M | +80.7% |
| FY2024 | -$56.4M | +31.8% |
| FY2023 | -$82.7M | -244.7% |
| FY2022 | -$24.0M | -188.2% |
| FY2021 | $27.2M | +45.2% |
| FY2020 | $18.7M | -41.2% |
| FY2019 | $31.8M | -2.2% |
| FY2018 | $32.5M | +5.8% |
| FY2017 | $30.8M | -19.7% |
| FY2016 | $38.3M | +86.2% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026